Across TCGA pan-cancer cohorts, HLA-DPB1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HLA-DPB1 data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher HLA-DPB1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-DPB1 expression acts as an unfavorable survival marker.

SKCM, LGG, and LUSC are the cancer types where HLA-DPB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.223	0.784	<.001	15	view →
LGG	OS	Median	All	0.306	0.811	.007	6	view →
LUSC	DFS	Median	All	0.158	0.645	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HLA-DPB1 tumor-vs-normal RNA expression · all HLA-DPB1 data types